RECRUITING

HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma

Conditions

Squamous Cell Carcinoma of the Oropharynx Radiation Therapy Radiotherapy Head Cancer Neck Cancer Low Dose Radiation HPV

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The study will evaluate the safety and effectiveness of a lower than standard dose of radiation for definitive or adjuvant treatment of head and neck squamous cell carcinomas.

Official Title

Circulating Tumor Modified HPV DNA-Guided Radiotherapy De-intensification of the Elective Neck (RaDEN) in Squamous Cell Carcinoma of the Head and Neck

Quick Facts

Study Start:2024-06-28

Study Completion:2029-11-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05962242

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, ≥ 18 years of age 4. Pathologically proven diagnosis of squamous cell carcinoma of the oropharynx of any AJCC 8th edition stage. 5. Eligible for and planning to receive definitive treatment or adjuvant treatment with radiotherapy. 6. Participants who are receiving concurrent systemic anticancer therapy (e.g. chemotherapy or immunotherapy) for oropharyngeal cancer are eligible. 1. For participants with T1-2 and N0 disease, chemotherapy is not required for eligibility. Participants may or may not receive chemotherapy per physician discretion. 2. For participants with T3-4 and/or N+ disease, chemotherapy is required for eligibility. 7. Participants may receive investigational agents with prior approval from the Principal Investigator. 8. ECOG Performance Status of 0-2. 9. p16 positive HPV as determined by NavDx and immunohistochemistry 10. For females of reproductive potential: agreement to use adequate contraception during radiation treatment and for 6 months (or more if applicable based on other medications) after the end of radiation treatment.	1. Evidence of distant metastatic disease 2. Prior history of radiotherapy to the head and/or neck 3. Had surgery for oropharyngeal cancer within 8 months of enrollment unless it was an incomplete oncologic surgery. Participant is eligible if the gross tumor was not completely removed. 4. Diagnosis of T3-4 and/or N+ disease with no plans to receive concurrent chemotherapy. 5. Diagnosis of a current or prior invasive malignancy (except non-melanoma skin cancer) unless the participant has been disease free for at least 3 years. 6. Participant is a prisoner 7. Known contraindications to head and neck radiation therapy such as ataxia telangiectasia or scleroderma. 8. Pregnancy or lactation 9. Active or severe co-morbidities as defined by the following: 1. Unstable angina and/or congestive heart failure requiring hospitalization up to 180 days before registration 2. Transmural myocardial infarction up to 180 days before registration 3. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration 4. Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration 5. Hepatic insufficiency as determined by the treating clinician resulting in clinical jaundice and/or coagulation effects or severe liver dysfunction. 6. Acquired immune deficiency syndrome (AIDS) based upon current CDC definition. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be slightly immunosuppressive. Protocol-specific requirements may also exclude immuno-compromised patients. 10. Tobacco smoking history of 10 pack years or greater, or ≥ 20 pack years if smoking cessation occurred at least 1 year prior to enrollment 11. Current use of antineoplastic drugs for other malignancies.

Inclusion Criteria

Exclusion Criteria

1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Male or female, ≥ 18 years of age
4. Pathologically proven diagnosis of squamous cell carcinoma of the oropharynx of any AJCC 8th edition stage.
5. Eligible for and planning to receive definitive treatment or adjuvant treatment with radiotherapy.
6. Participants who are receiving concurrent systemic anticancer therapy (e.g. chemotherapy or immunotherapy) for oropharyngeal cancer are eligible.
1. For participants with T1-2 and N0 disease, chemotherapy is not required for eligibility. Participants may or may not receive chemotherapy per physician discretion.
2. For participants with T3-4 and/or N+ disease, chemotherapy is required for eligibility.
7. Participants may receive investigational agents with prior approval from the Principal Investigator.
8. ECOG Performance Status of 0-2.
9. p16 positive HPV as determined by NavDx and immunohistochemistry
10. For females of reproductive potential: agreement to use adequate contraception during radiation treatment and for 6 months (or more if applicable based on other medications) after the end of radiation treatment.

1. Evidence of distant metastatic disease
2. Prior history of radiotherapy to the head and/or neck
3. Had surgery for oropharyngeal cancer within 8 months of enrollment unless it was an incomplete oncologic surgery. Participant is eligible if the gross tumor was not completely removed.
4. Diagnosis of T3-4 and/or N+ disease with no plans to receive concurrent chemotherapy.
5. Diagnosis of a current or prior invasive malignancy (except non-melanoma skin cancer) unless the participant has been disease free for at least 3 years.
6. Participant is a prisoner
7. Known contraindications to head and neck radiation therapy such as ataxia telangiectasia or scleroderma.
8. Pregnancy or lactation
9. Active or severe co-morbidities as defined by the following:
1. Unstable angina and/or congestive heart failure requiring hospitalization up to 180 days before registration
2. Transmural myocardial infarction up to 180 days before registration
3. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
4. Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
5. Hepatic insufficiency as determined by the treating clinician resulting in clinical jaundice and/or coagulation effects or severe liver dysfunction.
6. Acquired immune deficiency syndrome (AIDS) based upon current CDC definition. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be slightly immunosuppressive. Protocol-specific requirements may also exclude immuno-compromised patients.
10. Tobacco smoking history of 10 pack years or greater, or ≥ 20 pack years if smoking cessation occurred at least 1 year prior to enrollment
11. Current use of antineoplastic drugs for other malignancies.

Contacts and Locations

Study Contact

Song W

CONTACT

434-243-0008

UVARADONCClinicalTrials@uvahealth.org

Principal Investigator

Chris McLaughlin, M.D.

PRINCIPAL_INVESTIGATOR

UVA

Study Locations (Sites)

Miami Cancer Institute

Miami, Florida, 33176

United States

University of Virginia

Charlottesville, Virginia, 22908

United States

Eastern Virginia Medical School

Norfolk, Virginia, 23507

United States

Virginia Commonwealth University

Richmond, Virginia, 23284

United States

Collaborators and Investigators

Sponsor: University of Virginia

Chris McLaughlin, M.D., PRINCIPAL_INVESTIGATOR, UVA

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-28

Study Completion Date2029-11-01

Study Record Updates

Study Start Date2024-06-28

Study Completion Date2029-11-01

Terms related to this study

Keywords Provided by Researchers

Radiation Therapy
Radiotherapy
Head Cancer
Neck Cancer
Low Dose Radiation
HPV

Additional Relevant MeSH Terms

Squamous Cell Carcinoma of the Oropharynx